Why This Fast-Growing Dividend Stock Is a Buy
The dip in financial markets has led many investors to flock to stocks that are seen as high-yielding safe havens. This could partly explain why the pharma stock Merck (NYSE: MRK) has rallied 21% year to date while the S&P 500 index has dropped 18% during that time.
And even with the stock's massive gains thus far this year, Merck still looks like a buy. Let's dig into its fundamentals and valuation to learn why.
Last month, Merck reported results for the first quarter, ended March 31. And the company once again topped analysts' estimates.
Source Fool.com
